Literature DB >> 27329028

Treatment urgency: The importance of getting people with type 2 diabetes to target promptly.

Anne-Marie Felton1, James LaSalle2, Margaret McGill3.   

Abstract

The burgeoning population of individuals with type 2 diabetes provides challenges for management in terms of risk of diabetes-related complications. Early, intensive glycemic control particularly in newly-diagnosed people with type 2 diabetes has been shown to be beneficial in terms of reducing diabetic complications, indeed various national and international guidelines now routinely recommend intensive blood glucose control as an essential element of type 2 diabetes management. However, despite this, current management of glycemia is suboptimal and not enough people achieve their glucose targets worldwide. The Global Partnership for Effective Diabetes Management believe that an improved understanding of these contributing factors should enable the development of practice and guidance that will promote a drive toward better quality clinical outcomes.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clinical inertia; Comorbidities; Diabetes mellitus; Glycemic control; Hyperglycemia; Type 2

Mesh:

Substances:

Year:  2016        PMID: 27329028     DOI: 10.1016/j.diabres.2016.04.026

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  Impact of fear of hypoglycaemia on self-management in patients with type 2 diabetes mellitus: structural equation modelling.

Authors:  Shuang Li; Yehui Li; Lu Zhang; Yaxin Bi; Yan Zou; Lin Liu; Hong Zhang; Yuan Yuan; Weijuan Gong; Yu Zhang
Journal:  Acta Diabetol       Date:  2022-01-27       Impact factor: 4.280

2.  Impact of hypoglycemic episodes on health-related quality of life of type-2 diabetes mellitus patients: development and validation of a specific QoLHYPO© questionnaire.

Authors:  Domingo Orozco-Beltrán; Sara Artola; Margarida Jansà; Martin Lopez de la Torre-Casares; Eva Fuster
Journal:  Health Qual Life Outcomes       Date:  2018-03-23       Impact factor: 3.186

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.